In vivo magnetic resonance spectroscopy (MRS) is a safe and non-invasive tool which can be used to study aspects of brain chemistry and metabolism. Although a relatively recent technique in the field of psychiatric research, it has already been used in the study of anxiety and affective disorders, dementia, schizophrenia, and neurodevelopmental disorders.
Magnetic resonance spectroscopy can be used to extract in vivo biochemical information from body tissue. Like the more familiar magnetic resonance imaging (MRI) it is based on the principle that atomic nuclei within molecules behave like tiny magnets in the presence of an externally applied magnetic field and resonate at a characteristic frequency. MRS techniques have been used in in vitro biochemistry for many years but have only recently been employed in the study of biochemical changes in different organs of the living human body.
Although still a relatively new technique, MRS has been used in the study of numerous psychiatric disorders and has already yielded interesting results that may help to bridge the gap between clinical observation and neuroscience. The aims of this paper are to provide a basic and brief overview of the principles and technology of MRS and to summarise the major findings reported in psychiatric disorders.
Basic principles of MRS
Atomic nuclei with odd numbers of protons or neutrons behave like magnetic dipoles and rotate around an axis, like the Earth around its axis. The alignment of this axis is random. However, when atomic nuclei are placed in a powerful external magnetic field they tend to align along the direction of this field. When a second magnetic field is applied in the form of a brief pulse they absorb the extra energy and temporarily shift the orientation of their alignment. When the pulse is removed, they return to their original alignment and emit electromagnetic energy inducing a voltage signal. This signal can then be mathematically processed using Fourier transformation to yield the magnetic resonance spectrum.
Another concept basic to the understanding and interpretation of MRS findings is that of chemical shift. The rotation of atomic nuclei around their axis occurs at a frequency which is unique for each nucleus. This is called the Larmor frequency and is affected by the local magnetic fields surrounding a given nucleus. These local magnetic fields are generated by the electrons surrounding the nucleus. If these fields were absent, all the nuclei of a given atom would resonate at exactly the same frequency when placed in a homogeneous magnetic field. This would yield a single signal in the form of a sharp peak. However, because of the variation in local magnetic fields, the same nucleus in different molecules resonates at subtly different frequencies resulting in divergence from a single peak and giving rise to a spectrum. Chemical shift is the term used to describe this phenomenon of peak dispersion and allows for the discrimination, identification and quantification of different molecules.
Magneh'c resonance spectrum acquisition
The basic hardware required to undertake a clinical MRS study consists of a strong, homogeneous magnet (^ 1.5 T) and an appropriately tuned radiofrequency coil for the excitation and subsequent detection of the MR signal. The patient is typically asked to lie in the centre of a 50 cm bore superconducting magnet with a birdcage style antenna placed over the appropriate part of the body. Initially a set of conventional MR images are acquired in different planes to ascertain the desired neuroanatomical location for subsequent, volume localised MRS.
To localise the volume or 'voxel' of interest (typically in the shape of an 8 cc cube) a 'crossfire' technique is applied using a series of radiofrequency pulses and rapidly switching small magnetic field gradients. The application of these magnetic pulses forces the nuclei in the volume of interest to be 'tipped', that is shift their orientation. As the magnetic pulses are removed the nuclei 'relax' to their original alignment and the signal or 'echo' they emit is collected. This signal is then Fourier transformed to yield a spectrum with frequency on the horizontal axis and signal intensity on the vertical axis. Different chemicals are identified by the position of their peak along the frequency axis.
Acquisition sequences
There are several sequences that can be used for localisation and signal collection. The two main methods are called PRESS (Point RESolved Spectroscopy) and STEAM (STimulated Echo Acquisition Mode). The basic principles within each method are similar. PRESS involves the application of a series 90°-180°-180 c radiofrequency pulses in the presence of the appropriate gradients, whereas a 90°-90°-90° series is used in STEAM. PRESS sequence is better suited for metabolites that have long relaxation times (T 2 ), that is metabolites that relax slowly after excitation. Metabolites with short T 2 are less observable with PRESS and this results in some loss of information. However, the signal-to-noise ratio for an equivalent sequence is better with PRESS.
Types of MRS
The proton nucleus ( J H) in the hydrogen atom is the most commonly observed nucleus in MRS experiments. In MRI, one commonly collects the signal from hydrogen atoms in water and fat molecules, whereas in MRS, we concentrate on other hydrogen bearing neurochemicals such as aminoacids, neurotransmitters and their metabolites. The concentration of these neurochemicals is quite low (1/lOOOth that of body water) and their signal tends to be 'drowned' by that of the hydrogen in body water. However, the water signal can be 'suppressed' while leaving signals from other hydrogen bearing chemicals undisturbed (Fig. 1) .
The water-suppressed J H spectra from human brain can yield information about a number of biologically important molecules which include N-acetyl aspartate (NAA), a neuronal marker; neural membrane constituents such as choline containing compounds (Cho); neurotransmitters and their metabolites, such as glutamate and glutamine (Glx); cerebral sugars including wyo-inositol (ml); lactate, a marker of anaerobic glycolysis (Lac); and creatine (Cr).
Another commonly observed endogenous nucleus is the stable isotope of phosphorous, 31 P. Phosphorous MR data collection does not suffer from the same technical constraints as *H in terms of water suppression and fat elimination. However, the nucleus is inherently less sensitive than 1 H (6.65% sensitivity) requiring longer collection times or sampling of less discrete anatomical regions. 31 P MRS provides information about compounds involved in energy utilisation, such as phosphocreatine (PCr), adenosine di-and triphosphate (ADP, ATP) and inorganic phosphate (Pi). Some membrane phospholipids are also 'visible' with 31 P MRS. These include phosphomonoesters (PMEs) and phosphodiesters (PDEs) which are, respectively, precursors and breakdown products of membrane phospholipids and provide information about neuronal membrane metabolism. Other exogenous nuclei of interest to the psychiatrist that are sometimes observed in the form of labelled probes include 7 Li, 13 C and 19 F whose relative sensitivities to J H are 27.2%, 0.018% and 83.4%, respectively.
Psychiatric applications of MRS

Dementia
Most, but not all 1 ' 2 , 31 P MRS studies of Alzheimer's disease (AD) have shown abnormalities in the levels of membrane phospholipids and high energy metabolites that appear dependent on the severity of the illness 3 ' 4 . In normal ageing there is a decrease in PMEs accompanied with a concomitant increase in PDE levels which is different from the profile of biochemical change in AD 5 -6 . Pettegrew et al reported elevated PME levels in the initial stages of AD, compared to age matched controls 3 ' 5 . As the illness progresses PME levels drop. In contrast, PDE levels and high energy metabolites, such as PCr and Pi, appear to increase as the dementia worsens and seem to correlate with the number of senile plaques 3 . It has been proposed that the increase in PME reflects early, possibly causative, abnormalities in membrane metabolism while the increase of PDE and PCr reflect neuronal degeneration and death 3 ' 5 . *H MRS investigation of AD has revealed decrements in the levels of NAA, reflecting neuronal loss, with a parallel increase in myo-inositol 7 -8 . The latter finding suggests that abnormalities"-in the inositol polyphosphate second messenger system are present in AD. There is some preliminary evidence that biochemical abnormalities seen with MRS, such as a reduction in the NAA/Cr ratio 9 or the elevation in PME 5 , predate structural changes.
Several findings of interest have also emerged from MRS studies of degenerative dementias other than AD. Brown et al reported abnormally elevated PCr/Pi ratios in multi-infarct dementia, especially in the frontal cortical areas, compared to AD patients and age matched controls 10 . The authors proposed that this elevation in high energy metabolites represents either altered neuronal energy metabolism or astrocytic proliferation. In contrast, patients with AIDS Dementia Complex show a significant reduction in high energy phosphates with low ATP-to-Pi ratios 11 and reduced PCr and nucleotide triphosphate concentrations 12 . The biochemical profiles of the different diagnostic categories of degenerative dementias, as revealed by MRS, may be sufficiently different to allow for the application of this technique in the differential diagnosis of dementias. Shonk et al (1995) reported that AD could be distinguished from normal ageing with an 83% sensitivity and a 98% specificity and from other forms of dementia with an 82% sensitivity and 64% specificity 13 .
Schizophrenia
Using 31 P MRS, Pettegrew et al observed a reduction in PME levels and an increase in PDE levels in the dorsolateral prefrontal cortex in first episode drug naive schizophrenics 14 . The finding of decreased PME levels in the prefrontal cortex of schizophrenics has been replicated in more recent 31 P MRS studies 15 " 17 . Interestingly, PDE levels were only increased in patients at the early phases of schizophrenia and not in chronic cases 15 ' 17 . Preliminary evidence suggests that the alterations in PME and PDE levels in the prefrontal cortex may even predate the onset of psychosis 18 . The reported alterations in brain PME and PDE levels in schizophrenia are thought to reflect decreased synthesis and increased breakdown of neuronal membrane phospholipids.
Alterations in these membrane phospholipids in schizophrenia may vary not only with regard to the different stages of illness but also in different brain regions. 31 P MRS studies of the temporal and parietal lobes of schizophrenics have found no differences in PME or PDE levels 19 " 21 . Initial findings from 31 P MRS in schizophrenia suggest that the membrane phospholipid alterations persist with neuroleptic treatment and may represent trait markers 22 . Several findings of interest have also been reported in l H MRS studies of schizophrenia. Studies of temporal lobe structures have yielded conflicting results. One study reported reductions in NAA 23 in the right hippocampus/amygdala complex of schizophrenic patients, another found the NAA to be reduced primarily in the left hippocampus 24 and a third failed to find any difference between schizophrenics and controls 25 . Similarly, some studies reported frontal lobe reduction in NAA 25 while others failed to find any differences 26 . An interesting finding is the reduction in glutamate reported in the frontal lobes of drug-naive schizophrenics compared to controls 26 . Although in need of replication, this is consistent with the glutamate hypothesis of schizophrenia.
At this stage, any interpretation of the MRS findings in schizophrenia cannot be more than tentative. Changes in PME and PDE brain levels, similar to those seen in schizophrenics, are present in healthy controls during adolescence and again during normal ageing 27 . From this perspective, two contrasting hypotheses can be formulated. Schizophrenia could be associated with premature ageing although the metabolic alterations seen are distinct and different from those seen in degenerative dementias. Alternatively, abnormalities in brain maturational events that occur during adolescence may be present in schizophrenia 28 . These issues can be clarified by future longitudinal studies of schizophrenics and of subjects at increased genetic risk of schizophrenia. The reduction in NAA observed in some MRS studies in the frontal and temporal lobe of schizophrenics is consistent with reports of reduced volume of these structures in schizophrenia. Finally, MRS could prove useful in the study of neurotransmitter pathways such as glutamate in this disorder.
Anxiety disorders
*H MRS has been used to study metabolic abnormalities in panic disorder using lactate induced panic attacks as a model. Dager et al reported that the concentration of brain lactate at baseline, during and post lactate infusion was elevated in unmedicated patients with panic disorder compared to healthy controls 29 ' 30 . In contrast, medicated patients had brain lactate concentrations that were similar to controls at baseline, as well as during and after lactate infusion 30 . A similar disproportionate increase in brain lactate levels in the insular cortex was also seen in panic disorder patients during controlled hyperventilation 31 . These findings, if confirmed, demonstrate the capability of MRS to study potential chemical mechanisms in the production of panic attacks and evaluate the effect of treatment.
Neurodevelopmental disorders
Using J H MRS, Murata et al studied age related changes in peak area ratios of NAA, Cr and choline in a cross sectional sample of patients with Down's syndrome aged 20-46 years and compared them to age matched controls 32 . No age related changes were seen in the control sample. In contrast, Down's patients in the fifth decade of life showed an increase in the relative amount of choline in the absence of significant brain atrophy suggesting that metabolic abnormalities may precede neuronal loss.
Minshew et al used 31 P MRS to compare the metabolic profiles of the prefrontal cortex of 11 young autistic males with matched controls 33 . They reported a decrease in high energy phosphates such as PCr and ATP in the autistic subjects, indicative of increased energy utilisation. There was no group difference in the levels of PME and PDE. However, poor performance in neuropsychological tests was correlated with decreased levels of PME and high energy phosphates and increased levels of PDE independent of age or overall IQ. The authors hypothesised that increased energy utilisation and decreased neuronal membrane synthesis are possible biologic substrates for the neuropsychological abnormalities seen in autism.
Affective disorders
Kato et al published a number of 31 P MRS studies of patients suffering from bipolar I and II disorders 34 " 36 . Compared to controls, bipolar I patients showed increased PME and intracellular pH levels when either manic or depressed while the concentration of these metabolites was decreased when euthymic 34 ' 35 . In contrast, bipolar II patients had decreased PCr levels both during episodes and when euthymic 35 . In addition, increased levels of PME in bipolar II patients were only present during episodes while their pH levels were did not differ from controls at any stage 35 . These metabolic changes did not appear to be related to ventricular enlargement 36 or brain lithium concentration simultaneously determined by ^i MRS 37 .
MRS in psychiatric treatment
Lithium^L i MRS has been used for the in vivo investigation of the pharmacokinetic and metabolic characteristics of lithium administration in patients. Although accurate determination of brain lithium levels awaits further technical improvements of the MRS protocols applied, it is generally agreed that brain lithium concentration is about half that in the serum 38 "" 40 . Also, brain lithium levels appear to vary at different affective states 41 and seem to correlate with the degree of clinical improvement 42 .
Biological psychiatry
Neuroleptics
Studies of psychotic patients before and after initiation of neuroleptic treatment did not reveal any differences in 31 P MRS visible metabolites 22 . However, there was a significant positive correlation between PME levels at baseline and clinical improvement with treatment while baseline PDE levels showed a negative correlation 22 .
ECT Woods et al used
J H MRS to study the metabolic effects of ECT in the brain of depressed patients 43 . They were not able to demonstrate any significant increase in lactate, predicted by animal work. Instead, they observed an increase in the free fatty acid signal about 1-2 h following ECT administration, possibly reflecting the activation of the phosphatidylinositol system.
Limitations and future applications
The most important limitation of MRS is its relative lack of sensitivity. Only highly mobile nuclei can be studied and, so far, transient biochemical changes have been hard to detect. Problems of signal 'bleeding' between voxels and partial volume effects which are, at least partly, responsible for some of the inconsistencies in MRS research findings in psychiatry also need to be addressed. However, MRS technology is evolving rapidly. New and potentially more informative techniques are being developed such as chemical shift imaging. This method can be used in proton MRS and allows for the incorporation of biochemical data on a MRI image producing metabolite maps. The spatial resolution of these images is much lower than that of MRI but different neuroanatomical regions can be examined simultaneously.
MRS has a definite place in psychiatric research. This review illustrates the potential of MRS in providing new insights into abnormalities in pathophysiological mechanisms and neurotransmitter pathways in mental disorders in a way that no other current technique can. It also suggests that MRS may be a valuable tool in assessing pharmacokinetic and pharmacodynamic properties of psychiatric drugs and the metabolic effects of psychiatric treatment.
Although no firm conclusions can be drawn from the small number of studies available, MRS could eventually become a valuable clinical aid in establishing diagnosis and monitoring of illness progression as well as treatment response in mental disorders.
